Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More

PartnershipOpakalimPositive

AI Analysis

Summary

Biohaven has entered into a license agreement for Opakalim for epilepsy, with a buy rating reiterated by analysts. The deal represents a strategic partnership expansion for the company's epilepsy portfolio.

Outcome Details

License agreement for Opakalim

Importance:6/10

Sentiment:

0.50

licensingpartnershipepilepsybuy_rating

Related Companies

$BHVN

Read the original article

Published by Seeking Alpha Healthcare on August 27, 2026 6:21 PM

Read Original